Sorry, Internet Explorer and the old Edge Versions are not supported...
Please use an up-to-date Firefox, Chrome, Opera or the new Chromium based Edge to visit this website.

⚠️ You are using an old version of Edge. ⚠️

This browser can not support the full functionality of this website. For a better user experience we recommend to use the latest version of Edge or other up-to-date Browsers like Firefox, Chrome or Opera...

JOIN SYNAPSE

BOEHRINGER INGELHEIM’S INNOVATION PROGRAM BY BI X

Synapse is an innovation program run by BI X for Boehringer Ingelheim. This program is designed to foster partnerships between innovative startups, scaleups and more established companies and Boehringer Ingelheim, with the aim of disrupting the digital health landscape.

After a successful launch in France, BI X is now expanding the program internationally.

JOIN SYNAPSE

BOEHRINGER INGELHEIM’S INNOVATION PROGRAM BY BI X

Synapse is an innovation program run by BI X for Boehringer Ingelheim. This program is designed to foster partnerships between innovative startups, scaleups and more established companies and Boehringer Ingelheim, with the aim of disrupting the digital health landscape.

After a successful launch in France, BI X is now expanding the program internationally.

WHY JOIN SYNAPSE?

As a company collaborating with Boehringer Ingelheim on a pilot project, you will have the opportunity to establish connections with various business units and functions and to work with meaningful topics, facilitated by BI X. We are in search of companies with innovative solutions to contribute to the program topics outlined.

This fall, companies presenting the most ingenious and fitting solutions will be invited to engage with Boehringer Ingelheim business units on a paid pilot project.

Our long-term goal is to foster and scale successful partnerships that are mutually beneficial.

After an initial success in the healthcare field, we realized that this was an area that the team really liked and where our automated inspection technologies made a lot of sense. So, we looked for the best way to develop in the Pharma industry and Synapse is THE reference program in this field. And the fact that the program combines Industry 4.0, co-development, and health, for us it was a winning trio that would allow us to develop. So, we applied.

Rodolph Vogt, CEO, M-Cador

WHY JOIN SYNAPSE?

As a company collaborating with Boehringer Ingelheim on a pilot project, you will have the opportunity to establish connections with various business units and functions and to work with meaningful topics, facilitated by BI X. We are in search of companies with innovative solutions to contribute to the program topics outlined.

This fall, companies presenting the most ingenious and fitting solutions will be invited to engage with Boehringer Ingelheim business units on a paid pilot project.

Our long-term goal is to foster and scale successful partnerships that are mutually beneficial.

After an initial success in the healthcare field, we realized that this was an area that the team really liked and where our automated inspection technologies made a lot of sense. So, we looked for the best way to develop in the Pharma industry and Synapse is THE reference program in this field. And the fact that the program combines Industry 4.0, co-development, and health, for us it was a winning trio that would allow us to develop. So, we applied.

Rodolph Vogt, CEO, M-Cador

BENEFIT FROM A GLOBAL PLAYER

Boehringer Ingelheim is an international company with 52,000 employees in more than 130 countries.

At BI X, we are experts in digital health innovation, having successfully developed and launched numerous digital health solutions across various markets. By joining our program, you will gain access to Boehringer's extensive network of experts, contacts, and mentors, both internally and externally.

Synapse provides exclusive access to funding for testing and deploying projects, fostering an environment for your ideas to thrive and succeed.

BENEFIT FROM A GLOBAL PLAYER

Boehringer Ingelheim is an international company with 52,000 employees in more than 130 countries.

At BI X, we are experts in digital health innovation, having successfully developed and launched numerous digital health solutions across various markets. By joining our program, you will gain access to Boehringer's extensive network of experts, contacts, and mentors, both internally and externally.

Synapse provides exclusive access to funding for testing and deploying projects, fostering an environment for your ideas to thrive and succeed.

WHAT ARE WE LOOKING FOR

This time we are looking for startups working on one of the following challenges:

  • Increasing Diversity in Clinical Trials
  • Predictive Maintenance

Use the carousel on the right to read more about each topic.

WHAT ARE WE LOOKING FOR

This time we are looking for startups working on one of the following challenges:

  • Increasing Diversity in Clinical Trials
  • Predictive Maintenance

Use the carousel on the right to read more about each topic.

Diversity in Clinical Trials:

Clinical trials are crucial for understanding the safe and efficacy of new drugs, treatments, and medical devices. Investing in having a diverse patient group in the trials will ensure more applicable and reliable results applying to a diverse group of people and under-served communities.

We are interested in solutions that could help us in better understand diverse patient communities through data and information, reaching out the underserve patient communities and / or help in involving a diverse patient population in our trials. With this challenge we are focusing on the European market.

Diversity in Clinical Trials:

Clinical trials are crucial for understanding the safe and efficacy of new drugs, treatments, and medical devices. Investing in having a diverse patient group in the trials will ensure more applicable and reliable results applying to a diverse group of people and under-served communities.

We are interested in solutions that could help us in better understand diverse patient communities through data and information, reaching out the underserve patient communities and / or help in involving a diverse patient population in our trials. With this challenge we are focusing on the European market.

Predictive Maintenance:

Predictive maintenance is a data-driven approach to anticipate when equipment failure leading to unnecessary downtime could occur. We want to avoid downtime and proactively plan for maintenance activities. Data collection and analysis plays a crucial role in this approach. We are interested in companies working within this field with experience from the pharmaceutical industry.

If you have an innovative solution that fits the above challenges, we'd love to hear from you!

Predictive Maintenance:

Predictive maintenance is a data-driven approach to anticipate when equipment failure leading to unnecessary downtime could occur. We want to avoid downtime and proactively plan for maintenance activities. Data collection and analysis plays a crucial role in this approach. We are interested in companies working within this field with experience from the pharmaceutical industry.

If you have an innovative solution that fits the above challenges, we'd love to hear from you!

All Applications Have Been Successfully Received

The agenda for the program is outlined below.

Pilot Scoping Phase: May-June 2024

Startups pre-selected for the program will work with BI X and Boehringer Ingelheim experts to define the scope of their collaboration.

Selection Days: July 3-4 on-site in Ingelheim, Germany (attendance is mandatory for selected companies)

Selected companies will finalize and present their collaboration proposals to Boehringer Ingelheim decision makers for a decision to proceed to the pilot phase and for feedback.

Pilot phase: Fall 2024

Selected companies will conduct the planned pilot project together with Boehringer Ingelheim to explore and validate the scoped use case.

WHAT ELSE DO YOU NEED TO KNOW?

The accelerator program is free for all start-ups. All Boehringer Ingelheim/BI X requires is that start-ups give Boehringer Ingelheim priority right to participate in an initial cooperation project; maintain an open, transparent and constructive working relationship

Contact us: If you have any questions, please contact Eero Toppinen and Aino Heiska driving the operations of the program.

WHAT ELSE DO YOU NEED TO KNOW?

The accelerator program is free for all start-ups. All Boehringer Ingelheim/BI X requires is that start-ups give Boehringer Ingelheim priority right to participate in an initial cooperation project; maintain an open, transparent and constructive working relationship

Contact us: If you have any questions, please contact Eero Toppinen and Aino Heiska driving the operations of the program.

在勃林格数字化实验室里
©2022 BI X GmbH保留所有权利
A 勃林格殷格翰 company | Binger Strasse 173, 55216 Ingelheim / Rhein, 德国